Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
Foltynie T, Gandhi S, Gonzalez-Robles C, Zeissler ML, Mills G, Barker R, Carpenter J, Schrag A, Schapira A, Bandmann O, Mullin S, Duffen J, McFarthing K, Chataway J, Parmar M, Carroll C; EJS ACT-PD Consortium. Foltynie T, et al. Among authors: carroll c. Brain. 2023 Jul 3;146(7):2717-2722. doi: 10.1093/brain/awad063. Brain. 2023. PMID: 36856727 Free PMC article.
Tracking Parkinson's: Study Design and Baseline Patient Data.
Malek N, Swallow DM, Grosset KA, Lawton MA, Marrinan SL, Lehn AC, Bresner C, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG; PRoBaND. Malek N, et al. J Parkinsons Dis. 2015;5(4):947-59. doi: 10.3233/JPD-150662. J Parkinsons Dis. 2015. PMID: 26485428 Free PMC article.
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Schrag A, Carroll C, Duncan G, Molloy S, Grover L, Hunter R, Brown R, Freemantle N, Whipps J, Serfaty MA, Lewis G. Schrag A, et al. Among authors: carroll c. BMC Neurol. 2022 Dec 12;22(1):474. doi: 10.1186/s12883-022-02988-5. BMC Neurol. 2022. PMID: 36510237 Free PMC article.
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.
Martinez-Carrasco A, Real R, Lawton M, Iwaki H, Tan MMX, Wu L, Williams NM, Carroll C, Hu MTM, Grosset DG, Hardy J, Ryten M, Foltynie T, Ben-Shlomo Y, Shoai M, Morris HR. Martinez-Carrasco A, et al. Among authors: carroll c. medRxiv [Preprint]. 2023 May 30:2023.05.24.23290362. doi: 10.1101/2023.05.24.23290362. medRxiv. 2023. PMID: 37425912 Free PMC article. Updated. Preprint.
Genome-wide Analysis of Motor Progression in Parkinson Disease.
Martínez Carrasco A, Real R, Lawton M, Hertfelder Reynolds R, Tan M, Wu L, Williams N, Carroll C, Corvol JC, Hu M, Grosset D, Hardy J, Ryten M, Ben-Shlomo Y, Shoai M, Morris HR. Martínez Carrasco A, et al. Among authors: carroll c. Neurol Genet. 2023 Aug 8;9(5):e200092. doi: 10.1212/NXG.0000000000200092. eCollection 2023 Oct. Neurol Genet. 2023. PMID: 37560120 Free PMC article.
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.
Martinez-Carrasco A, Real R, Lawton M, Iwaki H, Tan MMX, Wu L, Williams NM, Carroll C, Hu MTM, Grosset DG, Hardy J, Ryten M, Foltynie T, Ben-Shlomo Y, Shoai M, Morris HR. Martinez-Carrasco A, et al. Among authors: carroll c. NPJ Parkinsons Dis. 2023 Aug 31;9(1):128. doi: 10.1038/s41531-023-00573-2. NPJ Parkinsons Dis. 2023. PMID: 37652906 Free PMC article.
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
Gonzalez-Robles C, Bartlett M, Burnell M, Clarke CS, Haar S, Hu MT, Huxford B, Jha A, Lawton M, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, van Wamelen D, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Weil RS, Schrag A; EJS ACT-PD Consortium. Gonzalez-Robles C, et al. Among authors: carroll cb. Mov Disord. 2024 Feb;39(2):433-438. doi: 10.1002/mds.29691. Epub 2023 Dec 22. Mov Disord. 2024. PMID: 38140767
Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial.
Jost ST, Aloui S, Evans J, Ashkan K, Sauerbier A, Rizos A, Petry-Schmelzer JN, Gronostay A, Fink GR, Visser-Vandewalle V, Antonini A, Silverdale M, Timmermann L, Martinez-Martin P, Chaudhuri KR, Dafsari HS; International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group and EUROPAR. Jost ST, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2352177. doi: 10.1001/jamanetworkopen.2023.52177. JAMA Netw Open. 2024. PMID: 38236600 Free PMC article. Clinical Trial.
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative.
Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, Krainc D, Matthews H, Moore DJ, Mursaleen L, Schwarzschild MA, Stott SRW, Sulzer D, Svenningsson P, Tanner CM, Carroll C, Simon DK, Brundin P. Wyse RK, et al. Among authors: carroll c. J Parkinsons Dis. 2024 Apr 5. doi: 10.3233/JPD-230363. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38578902 Review.
Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol.
Zeissler ML, Bakshi N, Bartlett M, Batla A, Byrom D, Chapman R, Collins S, Cowd E, Deeson E, Ellis-Doyle R, Forbes J, Gonzalez-Robles C, Jewell A, Lane EL, LaPelle NR, Martin K, Matthews H, Miller L, Mills G, Morgan A, Parry M, Pushparatnam K, Ratcliffe N, Salathiel D, Scurfield P, Siu C, Whipps S, Wonnacott S, Foltynie T, Carroll CB, McFarthing K; EJS ACT-PD consortium. Zeissler ML, et al. Among authors: carroll cb. J Parkinsons Dis. 2024 Apr 27. doi: 10.3233/JPD-230444. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38701161
1,220 results